Evolocumab Plus Statins Shows Significant Intracranial Plaque Regression Compared to Statins Alone: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-23 03:15 GMT | Update On 2025-08-23 04:56 GMT

China: A recent study published in the Journal of the American Heart Association has found that adding evolocumab—a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor—to standard statin therapy may significantly enhance intracranial atherosclerotic plaque regression compared with statin treatment alone.

The investigation, led by Xinzhi Hu and colleagues from the Department of Neurology at Peking Union Medical College Hospital, explored the impact of intensive lipid-lowering therapy on patients with intracranial atherosclerotic stenosis (ICAS).

Researchers analyzed data from a prospectively maintained high-resolution magnetic resonance imaging (MRI) database, focusing on individuals with ICAS of 50% or greater who had undergone two MRI evaluations over six months. The retrospective study included 179 statin-treated patients, divided into two groups: 50 patients who received additional evolocumab therapy and 129 patients who continued on statins alone.

The primary outcome was plaque response, defined as more than 5% regression in plaque size, while secondary outcomes included changes in plaque burden and stenosis degree. Statistical analyses using logistic and linear regression models assessed the association between evolocumab use and these imaging-based measures.

The study led to the following notable findings:

Patients receiving evolocumab with statins showed a clear advantage over those on statins alone.
Plaque regression was observed in 68% of the evolocumab group compared to 34.1% in the statin-only group.
Median plaque burden reduction was greater with combination therapy (–8.2%) versus statins alone (–1.9%).
Reduction in stenosis degree was also more pronounced in the evolocumab group (–15.3%) compared to statin monotherapy (–5.4%).
After adjustment for confounders, evolocumab use remained significantly associated with improved outcomes, with an odds ratio for plaque regression of 6.67.
Evolocumab users experienced a mean plaque burden reduction of 7.0% and a mean stenosis degree reduction of 20.3%.
Subgroup analyses confirmed these benefits were consistent regardless of statin intensity.

The authors noted that adding a PCSK9 inhibitor to statin therapy could offer a more effective approach for reversing intracranial atherosclerotic plaque, which is a major risk factor for ischemic stroke. These results suggest that such combination therapy might hold promise for improving vascular health in high-risk patients.

However, the researchers cautioned that their conclusions are based on a retrospective design, which may be subject to selection bias and other limitations. They called for prospective randomized controlled trials to confirm these observations and determine whether the combination therapy leads to improved clinical outcomes.

Reference:

Hu X, Liu Y, Yuan W, Zhang Z, Li S, Cheng A, Yu Q, Guo H, Zou Y, Li M, Liu C, Xu Y, Xu W. Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone. J Am Heart Assoc. 2025 Aug 19;14(16):e041251. doi: 10.1161/JAHA.124.041251. Epub 2025 Aug 18. PMID: 40820974.

Article Source : Journal of the American Heart Association

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Evolocumab Plus Statins Shows Significant Intracranial Plaque Regression Compared to Statins Alone: Study

Similar News

Chinese Herbal Foot-Baths Show Promise for Early-Stage Diabetic Foot Care: Study

Low-Dose Oral Minoxidil for Hair Loss Not Linked to Tachycardia, Large Study Suggests

Atopic Dermatitis Linked to 27 Percent Higher Stroke Risk, Meta-Analysis Finds

Early Rhythm Control Effective in Atrial Fibrillation Patients Regardless of Diabetes or Obesity Status: Study Shows

Hypertriglyceridemia Linked to Abdominal Aortic Aneurysm Risk: Study

This Diet May Cut Risk of Cancer and Heart Disease Multimorbidity: Study Suggests

Covert brain infarcts and white matter hyperintensities linked to increased fall risks: AHA